Tags

Type your tag names separated by a space and hit enter

Design and development of gliclazide-loaded chitosan for oral sustained drug delivery: in vitro/in vivo evaluation.
J Microencapsul. 2011; 28(2):122-33.JM

Abstract

Gliclazide (GLZ)/Chitosan microparticles were prepared with tripolyphosphate (TPP) by ionic cross-linking. The particle sizes of TPP-chitosan microparticles were in the range 675-887 µm and the loading efficiencies of drug was more than 94.0%. Chitosan concentration, TPP solution pH and glutaraldehyde volume added to the TPP cross-linking solution had an effect on the drug release characteristics. The microparticles were examined with scanning electron microscopy and infrared spectroscopy. Furthermore, pectin can interact with cationic chitosan on the surface of these TPP/chitosan microparticles to form a polyelectrolyte complex film for the improvement of the drug sustained-release performances. In vivo testing of the GLZ-chitosan microparticles in diabetic albino rabbits demonstrated significant antidiabetic effect of GLZ/chitosan microparticles after 8 h which lasts for 18 h, compared with GLZ powder which produced maximum hypoglycaemic effect after 4 h, suggesting that GLZ/chitosan microparticles are a valuable system for the long-term delivery of GLZ.

Authors+Show Affiliations

Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11495, PO Box 22452, Kingdom of Saudi Arabia. nsybarakat@yahoo.comNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21110773

Citation

Barakat, Nahla S., and Alanood S. Almurshedi. "Design and Development of Gliclazide-loaded Chitosan for Oral Sustained Drug Delivery: in Vitro/in Vivo Evaluation." Journal of Microencapsulation, vol. 28, no. 2, 2011, pp. 122-33.
Barakat NS, Almurshedi AS. Design and development of gliclazide-loaded chitosan for oral sustained drug delivery: in vitro/in vivo evaluation. J Microencapsul. 2011;28(2):122-33.
Barakat, N. S., & Almurshedi, A. S. (2011). Design and development of gliclazide-loaded chitosan for oral sustained drug delivery: in vitro/in vivo evaluation. Journal of Microencapsulation, 28(2), 122-33. https://doi.org/10.3109/02652048.2010.535621
Barakat NS, Almurshedi AS. Design and Development of Gliclazide-loaded Chitosan for Oral Sustained Drug Delivery: in Vitro/in Vivo Evaluation. J Microencapsul. 2011;28(2):122-33. PubMed PMID: 21110773.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Design and development of gliclazide-loaded chitosan for oral sustained drug delivery: in vitro/in vivo evaluation. AU - Barakat,Nahla S, AU - Almurshedi,Alanood S, Y1 - 2010/11/29/ PY - 2010/11/30/entrez PY - 2010/11/30/pubmed PY - 2011/4/26/medline SP - 122 EP - 33 JF - Journal of microencapsulation JO - J Microencapsul VL - 28 IS - 2 N2 - Gliclazide (GLZ)/Chitosan microparticles were prepared with tripolyphosphate (TPP) by ionic cross-linking. The particle sizes of TPP-chitosan microparticles were in the range 675-887 µm and the loading efficiencies of drug was more than 94.0%. Chitosan concentration, TPP solution pH and glutaraldehyde volume added to the TPP cross-linking solution had an effect on the drug release characteristics. The microparticles were examined with scanning electron microscopy and infrared spectroscopy. Furthermore, pectin can interact with cationic chitosan on the surface of these TPP/chitosan microparticles to form a polyelectrolyte complex film for the improvement of the drug sustained-release performances. In vivo testing of the GLZ-chitosan microparticles in diabetic albino rabbits demonstrated significant antidiabetic effect of GLZ/chitosan microparticles after 8 h which lasts for 18 h, compared with GLZ powder which produced maximum hypoglycaemic effect after 4 h, suggesting that GLZ/chitosan microparticles are a valuable system for the long-term delivery of GLZ. SN - 1464-5246 UR - https://www.unboundmedicine.com/medline/citation/21110773/Design_and_development_of_gliclazide_loaded_chitosan_for_oral_sustained_drug_delivery:_in_vitro/in_vivo_evaluation_ L2 - https://www.tandfonline.com/doi/full/10.3109/02652048.2010.535621 DB - PRIME DP - Unbound Medicine ER -